Overview
- Latest UK-funded modelling and IHME data project that unchecked antimicrobial resistance could cost the global economy up to $2 trn annually by 2050 and cause tens of millions of deaths.
- The UK’s cancellation of the £265m Fleming Fund and steep US foreign aid reductions threaten to undermine surveillance networks across Africa and Asia.
- Experts warn that without sustained funding and coordinated policy measures, resistance rates could shift in line with worst-case scenarios, driving up hospital admissions and treatment complexity.
- Health systems face soaring costs, with global AMR treatment expenses expected to rise by $176bn a year and US and UK bills climbing to nearly $57bn and $3.7bn respectively.
- International advocates are calling for restored aid budgets, accelerated development of new antibiotics and reinforced global monitoring to avert the escalating crisis.